Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
Integral Health Asset Management, LLC
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$2.1B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
90
positionsALL retained default holdings for this (filer, period), including NULL-value ones
30
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
26
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
INSMED INC COM PAR $.01position key pos:15087 · issuer key iss:1181 | add | +$27.7M | +250,000 | $218M | $245M | 1,250,000 | 1,500,000 | |
REVOLUTION MEDICINES INC COMposition key pos:15541 · issuer key iss:1842 | add | +$50.3M | +300,000 | $95.6M | $146M | 1,200,000 | 1,500,000 | |
CYTOKINETICS INC COM NEWposition key pos:13331 · issuer key iss:700 | add | +$16.5M | +200,000 | $89.0M | $105M | 1,400,000 | 1,600,000 | |
REVOLUTION MEDICINES INC COMposition key pos:15541 · issuer key iss:1842 PUT | new | +$72.9M | +750,000 | $0 | $72.9M | — | 750,000 | |
CYTOKINETICS INC COM NEWposition key pos:13331 · issuer key iss:700 CALL | add | +$34.1M | +500,000 | $31.8M | $65.9M | 500,000 | 1,000,000 | |
REGENERON PHARMACEUTICALS COMposition key pos:16027 · issuer key iss:1826 | trim | −$15.4M | −20,000 | $81.0M | $65.7M | 105,000 | 85,000 | |
VERA THERAPEUTICS INC CL Aposition key sid:sec:prov:c6f0567aff349dfe2dab4a6ee5ba8988 · issuer key cusip6:92337R | trim | −$26.8M | −200,000 | $91.2M | $64.4M | 1,800,000 | 1,600,000 | |
CARDINAL HEALTH INC COMposition key pos:16209 · issuer key iss:516 | add | +$16.0M | +70,000 | $41.1M | $57.1M | 200,000 | 270,000 | |
ROIVANT SCIENCES LTD SHSposition key pos:18572 · issuer key iss:2604 | add | +$37.0M | +1,150,000 | $18.4M | $55.4M | 850,000 | 2,000,000 | |
BRIGHTSPRING HEALTH SVCS INC COMposition key pos:19170 · issuer key iss:432 | add | +$25.2M | +500,000 | $28.1M | $53.3M | 750,000 | 1,250,000 | |
RHYTHM PHARMACEUTICALS INC COMposition key pos:17607 · issuer key iss:1846 | add | +$1.3M | +125,000 | $50.8M | $52.2M | 475,000 | 600,000 | |
MERCK & CO INC COMposition key pos:18668 · issuer key iss:1461 | add | +$24.8M | +175,000 | $26.3M | $51.1M | 250,000 | 425,000 | |
EDGEWISE THERAPEUTICS INC COMposition key pos:12663 · issuer key iss:796 | add | +$13.2M | +100,000 | $37.2M | $50.4M | 1,500,000 | 1,600,000 | |
ASTRAZENECA PLC ORDposition key pos:18610 · issuer key iss:2433 | new | +$49.3M | +250,000 | $0 | $49.3M | — | 250,000 | |
REVOLUTION MEDICINES INC COMposition key pos:15541 · issuer key iss:1842 CALL | new | +$48.6M | +500,000 | $0 | $48.6M | — | 500,000 | |
ALIGNMENT HEALTHCARE INC COMposition key pos:13470 · issuer key iss:135 | add | +$1.9M | +375,000 | $43.5M | $45.4M | 2,200,000 | 2,575,000 | |
BOSTON SCIENTIFIC CORP COMposition key pos:14974 · issuer key iss:423 | add | +$13.1M | +325,000 | $21.5M | $34.5M | 225,000 | 550,000 | |
LIFESTANCE HEALTH GROUP INC COMposition key pos:16008 · issuer key iss:1352 | add | +$6.3M | +1,300,000 | $21.1M | $27.4M | 3,000,000 | 4,300,000 | |
ASCENDIS PHARMA A/S SPONSORED ADRposition key pos:16862 · issuer key iss:252 | add | +$7.1M | +25,000 | $19.2M | $26.3M | 90,000 | 115,000 | |
SCHOLAR ROCK HLDG CORP COMposition key pos:18628 · issuer key iss:1936 | add | +$11.4M | +200,000 | $13.2M | $24.6M | 300,000 | 500,000 | |
ELEVANCE HEALTH INC FORMERLY COMposition key pos:15934 · issuer key iss:207 | add | +$923K | +15,000 | $21.0M | $22.0M | 60,000 | 75,000 | |
BRIDGEBIO PHARMA INC COMposition key pos:15468 · issuer key iss:427 | new | +$20.4M | +275,000 | $0 | $20.4M | — | 275,000 | |
GLAUKOS CORP COMposition key pos:16702 · issuer key iss:1012 | trim | −$17.9M | −150,000 | $36.7M | $18.8M | 325,000 | 175,000 | |
ARROWHEAD PHARMACEUTICALS IN COMposition key pos:16618 · issuer key iss:249 | add | +$12.2M | +200,000 | $6.6M | $18.8M | 100,000 | 300,000 | |
VERTEX PHARMACEUTICALS INC COMposition key pos:11430 · issuer key iss:2265 | new | +$17.9M | +40,000 | $0 | $17.9M | — | 40,000 | |
ORIC PHARMACEUTICALS INC COMposition key pos:11546 · issuer key iss:1634 | add | +$7.9M | +200,000 | $9.8M | $17.7M | 1,200,000 | 1,400,000 | |
ALUMIS INC COMposition key pos:17057 · issuer key iss:158 | new | +$17.6M | +800,000 | $0 | $17.6M | — | 800,000 | |
FRESENIUS MEDICAL CARE AG SPONSORED ADRposition key sid:sec:prov:a6f31b4733de62bae5fced1fb39b0119 · issuer key cusip6:358029 | add | +$2.0M | +125,000 | $15.5M | $17.5M | 650,000 | 775,000 | |
INTUITIVE SURGICAL INC COM NEWposition key pos:17712 · issuer key iss:1213 | trim | −$46.2M | −75,000 | $62.3M | $16.1M | 110,000 | 35,000 | |
GILEAD SCIENCES INC COMposition key pos:11444 · issuer key iss:1008 | new | +$13.9M | +100,000 | $0 | $13.9M | — | 100,000 | |
ELI LILLY & CO COMposition key pos:16757 · issuer key iss:1353 | trim | −$7.7M | −5,000 | $21.5M | $13.8M | 20,000 | 15,000 | |
EDWARDS LIFESCIENCES CORP COMposition key pos:17342 · issuer key iss:799 | trim | −$14.1M | −155,000 | $27.7M | $13.6M | 325,000 | 170,000 | |
MINERALYS THERAPEUTICS INC COMposition key sid:sec:prov:d00159df48fd34cc806ae902a076ba0a · issuer key cusip6:603170 CALL | add | +$4.5M | +250,000 | $9.1M | $13.5M | 250,000 | 500,000 | |
COGENT BIOSCIENCES INC COMposition key pos:18333 · issuer key iss:610 | new | +$13.5M | +350,000 | $0 | $13.5M | — | 350,000 | |
ELANCO ANIMAL HEALTH INC COMposition key pos:16287 · issuer key iss:802 | add | +$7.5M | +300,000 | $5.7M | $13.2M | 250,000 | 550,000 | |
MADRIGAL PHARMACEUTICALS INC COMposition key pos:15238 · issuer key iss:1407 | new | +$13.1M | +25,000 | $0 | $13.1M | — | 25,000 | |
DIANTHUS THERAPEUTICS INC COMposition key pos:18462 · issuer key iss:731 | trim | +$1.3M | −125,000 | $11.3M | $12.6M | 275,000 | 150,000 | |
REGENXBIO INC COMposition key sid:sec:prov:e7743277455b5823374498b009dffbbe · issuer key cusip6:75901B | add | −$4.7M | +300,000 | $17.3M | $12.6M | 1,200,000 | 1,500,000 | |
QUEST DIAGNOSTICS INC COMposition key pos:13299 · issuer key iss:1793 | trim | −$1.3M | −15,000 | $13.0M | $11.8M | 75,000 | 60,000 | |
XENON PHARMACEUTICALS INC COMposition key pos:13384 · issuer key iss:2365 | new | +$11.6M | +200,000 | $0 | $11.6M | — | 200,000 | |
ERASCA INC COMposition key pos:12600 · issuer key iss:846 | new | +$11.3M | +700,000 | $0 | $11.3M | — | 700,000 | |
ALTO NEUROSCIENCE INC COM SHSposition key sid:sec:prov:d8f1dce881f876173d775baaae476159 · issuer key cusip6:02157Q | add | +$4.6M | +125,000 | $6.7M | $11.2M | 375,000 | 500,000 | |
BIOGEN INC COMposition key pos:12302 · issuer key iss:376 | trim | −$6.6M | −40,000 | $17.6M | $11.0M | 100,000 | 60,000 | |
DEXCOM INC COMposition key pos:15920 · issuer key iss:727 | trim | −$22.2M | −325,000 | $33.2M | $11.0M | 500,000 | 175,000 | |
DISC MEDICINE INC COMposition key pos:13022 · issuer key iss:741 | new | +$10.9M | +170,000 | $0 | $10.9M | — | 170,000 | |
NURIX THERAPEUTICS INC COMposition key sid:sec:prov:48ac0f50c981e01f7c5af17d58a117cf · issuer key cusip6:67080M | add | +$5.2M | +400,000 | $5.7M | $10.9M | 300,000 | 700,000 | |
CVS HEALTH CORP COMposition key pos:14228 · issuer key iss:489 | trim | −$28.9M | −350,000 | $39.7M | $10.8M | 500,000 | 150,000 | |
COOPER COS INC COMposition key pos:17918 · issuer key iss:650 | trim | −$15.9M | −175,000 | $26.6M | $10.7M | 325,000 | 150,000 | |
THERMO FISHER SCIENTIFIC INC COMposition key pos:16012 · issuer key iss:2132 | new | +$9.8M | +20,000 | $0 | $9.8M | — | 20,000 | |
LIVANOVA PLC SHSposition key pos:11842 · issuer key iss:2558 | new | +$9.5M | +150,000 | $0 | $9.5M | — | 150,000 | |
LANTHEUS HLDGS INC COMposition key pos:14656 · issuer key iss:1326 | add | +$2.8M | +25,000 | $6.7M | $9.5M | 100,000 | 125,000 | |
TANGO THERAPEUTICS INC COMposition key pos:12388 · issuer key iss:2086 | add | +$7.6M | +250,000 | $1.8M | $9.4M | 200,000 | 450,000 | |
IONIS PHARMACEUTICALS INC COMposition key pos:12370 · issuer key iss:1221 | new | +$9.4M | +125,000 | $0 | $9.4M | — | 125,000 | |
SANA BIOTECHNOLOGY INC COMposition key sid:sec:prov:7ff2ed7cd5581a47f16a78be72caca7a · issuer key cusip6:799566 | add | −$3.0M | +200,000 | $12.2M | $9.2M | 3,000,000 | 3,200,000 | |
PROTARA THERAPEUTICS INC COM STKposition key sid:sec:prov:f702a4fd275ccf1ac7ea45ff5986f07c · issuer key cusip6:74365U | trim | −$2.9M | −500,000 | $12.0M | $9.1M | 2,250,000 | 1,750,000 | |
ENVISTA HOLDINGS CORPORATION COMposition key pos:12516 · issuer key iss:835 | trim | −$2.0M | −150,000 | $10.9M | $8.9M | 500,000 | 350,000 | |
BIOHAVEN LTD COMposition key pos:14561 · issuer key iss:2447 | trim | −$8.5M | −500,000 | $16.9M | $8.5M | 1,500,000 | 1,000,000 | |
SYNDAX PHARMACEUTICALS INC COMposition key sid:sec:prov:eb359106a5c4d721cdc955ced4da0795 · issuer key cusip6:87164F | add | +$4.0M | +150,000 | $4.2M | $8.2M | 200,000 | 350,000 | |
VIKING THERAPEUTICS INC COMposition key pos:17730 · issuer key iss:2273 | add | +$4.6M | +150,000 | $3.5M | $8.1M | 100,000 | 250,000 | |
DEFINIUM THERAPEUTICS INC COM SHSposition key pos:17580 · issuer key iss:717 | new | +$7.6M | +400,000 | $0 | $7.6M | — | 400,000 | |
BEAM THERAPEUTICS INC COMposition key sid:sec:prov:fbdfb263adbfc86bd605b695db4205d4 · issuer key cusip6:07373V | trim | −$8.1M | −250,000 | $15.2M | $7.1M | 550,000 | 300,000 | |
CAPRICOR THERAPEUTICS INC COM NEWposition key sid:sec:prov:f5ab5fc62f8ffc42012ac685dc8651c0 · issuer key cusip6:14070B | new | +$6.1M | +200,000 | $0 | $6.1M | — | 200,000 | |
IQVIA HLDGS INC COMposition key pos:17397 · issuer key iss:1223 | new | +$6.0M | +35,000 | $0 | $6.0M | — | 35,000 | |
AXSOME THERAPEUTICS INC. COMposition key pos:13938 · issuer key iss:295 | new | +$5.9M | +35,000 | $0 | $5.9M | — | 35,000 | |
PROTAGONIST THERAPEUTICS INC COMposition key pos:14826 · issuer key iss:1773 | new | +$5.3M | +50,000 | $0 | $5.3M | — | 50,000 | |
EVOMMUNE INC COM SHSposition key sid:sec:prov:adbff6ad799c41f5a1fe4cddc6ffc42b · issuer key cusip6:30054Y | add | +$3.0M | +100,000 | $2.1M | $5.2M | 125,000 | 225,000 | |
ACADIA HEALTHCARE COMPANY IN COMposition key pos:13278 · issuer key iss:55 | new | +$4.7M | +200,000 | $0 | $4.7M | — | 200,000 | |
ZIMMER BIOMET HOLDINGS INC COMposition key pos:13281 · issuer key iss:2378 | new | +$4.5M | +50,000 | $0 | $4.5M | — | 50,000 | |
FORTE BIOSCIENCES INC COM NEWposition key sid:sec:prov:fcb734c2b01cb725ac58cb009a803c4c · issuer key cusip6:34962G | new | +$3.9M | +150,000 | $0 | $3.9M | — | 150,000 | |
LB PHARMACEUTICALS INC COM SHSposition key sid:sec:prov:be515631054470e2500985b7cc1d1245 · issuer key cusip6:50180M | add | +$1.5M | +50,000 | $2.2M | $3.7M | 100,000 | 150,000 | |
SAVARA INC COMposition key sid:sec:prov:2bc6a25d40cf07124e3a03bdecf4a4df · issuer key cusip6:805111 | new | +$3.3M | +600,000 | $0 | $3.3M | — | 600,000 | |
RELMADA THERAPEUTICS INC COMposition key sid:sec:prov:0492e747c8d37a4dab1ade9330576c2c · issuer key cusip6:75955J | new | +$3.1M | +450,000 | $0 | $3.1M | — | 450,000 | |
IMMUNOCORE HLDGS PLC ADSposition key pos:16434 · issuer key iss:1166 | new | +$3.0M | +100,000 | $0 | $3.0M | — | 100,000 | |
INHIBIKASE THERAPEUTICS INC COM NEWposition key sid:sec:prov:8cb65945c1d745d32abfa3ce25a4d2e9 · issuer key cusip6:45719W | trim | −$1.3M | −400,000 | $3.6M | $2.3M | 1,750,000 | 1,350,000 | |
OLEMA PHARMACEUTICALS INC COMposition key pos:14811 · issuer key iss:1615 | new | +$2.2M | +150,000 | $0 | $2.2M | — | 150,000 | |
INVENTIVA SA ADSposition key sid:sec:prov:36f6260da0bf69546f0e601e6d5bafdc · issuer key cusip6:46124U | new | +$2.2M | +400,000 | $0 | $2.2M | — | 400,000 | |
SIONNA THERAPEUTICS INC COMposition key pos:11054 · issuer key iss:1980 | new | +$2.0M | +50,000 | $0 | $2.0M | — | 50,000 | |
UNICYCIVE THERAPEUTICS INC COM NEWposition key sid:sec:prov:dfd0154b493c84f8cf2ed4d228add022 · issuer key cusip6:90466Y | new | +$1.5M | +225,000 | $0 | $1.5M | — | 225,000 | |
| pos:11227 | exit‡e | −$31.1M | −100,000 | $31.1M | $0 | 100,000 | — | |
| pos:11987 | exit‡e | −$14.3M | −200,000 | $14.3M | $0 | 200,000 | — | |
| pos:12813 | exit‡e | −$5.9M | −125,000 | $5.9M | $0 | 125,000 | — | |
| pos:13207 | exit‡e | −$23.1M | −130,000 | $23.1M | $0 | 130,000 | — | |
| pos:14280 | exit‡e | −$64.8M | −675,000 | $64.8M | $0 | 675,000 | — | |
| pos:14444 | exit‡e | −$6.9M | −75,000 | $6.9M | $0 | 75,000 | — | |
| pos:15352 | exit‡e | −$2.9M | −200,000 | $2.9M | $0 | 200,000 | — | |
| pos:15751 | exit‡e | −$31.2M | −1,000,000 | $31.2M | $0 | 1,000,000 | — | |
| pos:15962 | exit‡e | −$1.6M | −200,000 | $1.6M | $0 | 200,000 | — | |
| pos:16018 | exit‡e | −$23.9M | −60,000 | $23.9M | $0 | 60,000 | — | |
| pos:17013 | exit‡e | −$16.5M | −50,000 | $16.5M | $0 | 50,000 | — | |
| pos:17085 | exit‡e | −$30.5M | −250,000 | $30.5M | $0 | 250,000 | — | |
| pos:17857 | exit‡e | −$9.0M | −45,000 | $9.0M | $0 | 45,000 | — | |
| pos:18040 | exit‡e | −$19.9M | −100,000 | $19.9M | $0 | 100,000 | — | |
| pos:18046 | exit‡e | −$17.7M | −400,000 | $17.7M | $0 | 400,000 | — | |
| pos:18229 | exit‡e | −$10.6M | −100,000 | $10.6M | $0 | 100,000 | — | |
| pos:18367 | exit‡e | −$32.2M | −350,000 | $32.2M | $0 | 350,000 | — | |
| pos:18385 | exit‡e | −$17.2M | −425,000 | $17.2M | $0 | 425,000 | — | |
| sid:sec:prov:08b4ddd7740553d5019530b2d4dd293b | exit‡e | −$3.4M | −425,000 | $3.4M | $0 | 425,000 | — | |
| sid:sec:prov:1e348df3cde91ba41d5ebeef0c53e107 | exit‡e | −$20.4M | −750,000 | $20.4M | $0 | 750,000 | — | |
| sid:sec:prov:233302be8852a126d4f3dc726082a4c4 | exit‡e | −$5.0M | −200,000 | $5.0M | $0 | 200,000 | — | |
| sid:sec:prov:3044f98940a2897deb445091c04637d0 | exit‡e | −$4.7M | −350,000 | $4.7M | $0 | 350,000 | — |
80 more changes below.
1–100 of 104 changes
Mark-to-market only (no share change) · 12
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
NOVARTIS AG SPONSORED ADRposition key pos:15241 · issuer key iss:1585 | no change | +$3.7M | 0 | $34.5M | $38.2M | 250,000 | 250,000 | |
CENTENE CORP DEL COMposition key pos:13554 · issuer key iss:546 | no change | −$5.5M | 0 | $26.7M | $21.3M | 650,000 | 650,000 | |
MINERALYS THERAPEUTICS INC COMposition key sid:sec:prov:d00159df48fd34cc806ae902a076ba0a · issuer key cusip6:603170 | no change | −$6.9M | 0 | $27.2M | $20.3M | 750,000 | 750,000 | |
NEUROCRINE BIOSCIENCES INC COMposition key pos:12315 · issuer key iss:1552 | no change | −$1.5M | 0 | $21.3M | $19.8M | 150,000 | 150,000 | |
UNIQURE NV SHSposition key pos:11923 · issuer key iss:2710 | no change | −$6.8M | 0 | $21.5M | $14.7M | 900,000 | 900,000 | |
TARSUS PHARMACEUTICALS INC COMposition key pos:11454 · issuer key iss:2092 | no change | −$2.3M | 0 | $16.4M | $14.0M | 200,000 | 200,000 | |
PRAXIS PRECISION MEDICINES I COM NEWposition key pos:11991 · issuer key iss:1748 | no change | +$1.1M | 0 | $11.8M | $12.9M | 40,000 | 40,000 | |
SOLENO THERAPEUTICS INC COMposition key sid:sec:prov:9c654c0b85e21e330a7ebfd2ced217c7 · issuer key cusip6:834203 | no change | −$4.2M | 0 | $15.0M | $10.9M | 325,000 | 325,000 | |
CELCUITY INC COMposition key pos:11232 · issuer key iss:542 | no change | +$1.2M | 0 | $8.0M | $9.1M | 80,000 | 80,000 | |
REZOLUTE INC COM NEWposition key sid:sec:prov:cb2ee571f458a0a64c1c152656def847 · issuer key cusip6:76200L | no change | +$1.4M | 0 | $4.7M | $6.1M | 2,000,000 | 2,000,000 | |
MAZE THERAPEUTICS INC COMposition key pos:16236 · issuer key iss:1445 | no change | −$1.2M | 0 | $4.1M | $3.0M | 100,000 | 100,000 | |
TENAX THERAPEUTICS INC COM NEWposition key sid:sec:prov:9e958f4e10d0d474cc9e75d42ea33a9a · issuer key cusip6:88032L | no change | +$635K | 0 | $2.0M | $2.7M | 167,000 | 167,000 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 70.0%below median 80.0%
- Concentration index
- 339 bpsbelow median 446 bps
- Positions with value
- 90 / 90median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 70.0% · HHI (bps) ·§: 339integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 116
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open Integral Health Asset Management, LLC's 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–86 of 86 issuers · $2.1B disclosed value over 90 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | RVMDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REVOLUTION MEDICINES INC3 positions · 3 reported rows
| $267M | 2,750,000 | — | 12.8% | — | ||||||||||
| — | INSMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INSMED INC INSMED INC · COM PAR $.01 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $245M | 1,500,000 | — | 11.7% | — | ||||||||||
| — | CYTKverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CYTOKINETICS INC | $171M | 2,600,000 | — | 8.2% | — | ||||||||||
| — | REGNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REGENERON PHARMACEUTICALS REGENERON PHARMACEUTICALS · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $65.7M | 85,000 | — | 3.1% | — | ||||||||||
| — | — | VERA THERAPEUTICS INC VERA THERAPEUTICS INC · CL A CUSIP 92337R101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $64.4M | 1,600,000 | — | 3.1% | — | ||||||||||
| — | CAHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CARDINAL HEALTH INC CARDINAL HEALTH INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $57.1M | 270,000 | — | 2.7% | — | ||||||||||
| — | ROIVverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ROIVANT SCIENCES LTD ROIVANT SCIENCES LTD · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $55.4M | 2,000,000 | — | 2.6% | — | ||||||||||
| — | BTSGverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BRIGHTSPRING HEALTH SVCS INC BRIGHTSPRING HEALTH SVCS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $53.3M | 1,250,000 | — | 2.5% | — | ||||||||||
| — | RYTMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | RHYTHM PHARMACEUTICALS INC RHYTHM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $52.2M | 600,000 | — | 2.5% | — | ||||||||||
| — | MRKverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MERCK & CO INC MERCK & CO INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $51.1M | 425,000 | — | 2.4% | — | ||||||||||
| — | EWTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | EDGEWISE THERAPEUTICS INC EDGEWISE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $50.4M | 1,600,000 | — | 2.4% | — | ||||||||||
| — | AZNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ASTRAZENECA PLC ASTRAZENECA PLC · ORD CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $49.3M | 250,000 | — | 2.4% | — | ||||||||||
| — | — | ALIGNMENT HEALTHCARE INC ALIGNMENT HEALTHCARE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $45.4M | 2,575,000 | — | 2.2% | — | ||||||||||
| — | NVSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NOVARTIS AG NOVARTIS AG · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $38.2M | 250,000 | — | 1.8% | — | ||||||||||
| — | BSXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BOSTON SCIENTIFIC CORP BOSTON SCIENTIFIC CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $34.5M | 550,000 | — | 1.7% | — | ||||||||||
| — | — | MINERALYS THERAPEUTICS INC | $33.9M | 1,250,000 | — | 1.6% | — | ||||||||||
| — | LFSTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | LIFESTANCE HEALTH GROUP INC LIFESTANCE HEALTH GROUP INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $27.4M | 4,300,000 | — | 1.3% | — | ||||||||||
| — | ASNDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ASCENDIS PHARMA A/S ASCENDIS PHARMA A/S · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $26.3M | 115,000 | — | 1.3% | — | ||||||||||
| — | SRRKverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SCHOLAR ROCK HLDG CORP SCHOLAR ROCK HLDG CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $24.6M | 500,000 | — | 1.2% | — | ||||||||||
| — | ELVverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ELEVANCE HEALTH INC FORMERLY ELEVANCE HEALTH INC FORMERLY · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $22.0M | 75,000 | — | 1.1% | — | ||||||||||
| — | CNCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CENTENE CORP DEL CENTENE CORP DEL · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $21.3M | 650,000 | — | 1.0% | — | ||||||||||
| — | BBIOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BRIDGEBIO PHARMA INC BRIDGEBIO PHARMA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $20.4M | 275,000 | — | 1.0% | — | ||||||||||
| — | NBIXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NEUROCRINE BIOSCIENCES INC NEUROCRINE BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.8M | 150,000 | — | 0.9% | — | ||||||||||
| — | GKOSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GLAUKOS CORP GLAUKOS CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.8M | 175,000 | — | 0.9% | — | ||||||||||
| — | ARWRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ARROWHEAD PHARMACEUTICALS IN ARROWHEAD PHARMACEUTICALS IN · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.8M | 300,000 | — | 0.9% | — | ||||||||||
| — | VRTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VERTEX PHARMACEUTICALS INC VERTEX PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.9M | 40,000 | — | 0.9% | — | ||||||||||
| — | ORICverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ORIC PHARMACEUTICALS INC ORIC PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.7M | 1,400,000 | — | 0.8% | — | ||||||||||
| — | ALMSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ALUMIS INC ALUMIS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.6M | 800,000 | — | 0.8% | — | ||||||||||
| — | — | FRESENIUS MEDICAL CARE AG FRESENIUS MEDICAL CARE AG · SPONSORED ADR CUSIP 358029106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.5M | 775,000 | — | 0.8% | — | ||||||||||
| — | ISRGverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INTUITIVE SURGICAL INC INTUITIVE SURGICAL INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $16.1M | 35,000 | — | 0.8% | — | ||||||||||
| — | QUREverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | UNIQURE NV UNIQURE NV · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.7M | 900,000 | — | 0.7% | — | ||||||||||
| — | TARSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TARSUS PHARMACEUTICALS INC TARSUS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.0M | 200,000 | — | 0.7% | — | ||||||||||
| — | GILDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GILEAD SCIENCES INC GILEAD SCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.9M | 100,000 | — | 0.7% | — | ||||||||||
| — | LLYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ELI LILLY & CO ELI LILLY & CO · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.8M | 15,000 | — | 0.7% | — | ||||||||||
| — | EWverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | EDWARDS LIFESCIENCES CORP EDWARDS LIFESCIENCES CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.6M | 170,000 | — | 0.7% | — | ||||||||||
| — | COGTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | COGENT BIOSCIENCES INC COGENT BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.5M | 350,000 | — | 0.6% | — | ||||||||||
| — | ELANverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ELANCO ANIMAL HEALTH INC ELANCO ANIMAL HEALTH INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.2M | 550,000 | — | 0.6% | — | ||||||||||
| — | MDGLverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MADRIGAL PHARMACEUTICALS INC MADRIGAL PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.1M | 25,000 | — | 0.6% | — | ||||||||||
| — | PRAXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PRAXIS PRECISION MEDICINES I PRAXIS PRECISION MEDICINES I · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $12.9M | 40,000 | — | 0.6% | — | ||||||||||
| — | DNTHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DIANTHUS THERAPEUTICS INC DIANTHUS THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $12.6M | 150,000 | — | 0.6% | — | ||||||||||
| — | — | REGENXBIO INC REGENXBIO INC · COM CUSIP 75901B107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $12.6M | 1,500,000 | — | 0.6% | — | ||||||||||
| — | DGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | QUEST DIAGNOSTICS INC QUEST DIAGNOSTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.8M | 60,000 | — | 0.6% | — | ||||||||||
| — | XENEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | XENON PHARMACEUTICALS INC XENON PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.6M | 200,000 | — | 0.6% | — | ||||||||||
| — | ERASverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ERASCA INC ERASCA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.3M | 700,000 | — | 0.5% | — | ||||||||||
| — | — | ALTO NEUROSCIENCE INC ALTO NEUROSCIENCE INC · COM SHS CUSIP 02157Q109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.2M | 500,000 | — | 0.5% | — | ||||||||||
| — | BIIBverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIOGEN INC BIOGEN INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.0M | 60,000 | — | 0.5% | — | ||||||||||
| — | DXCMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DEXCOM INC DEXCOM INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.0M | 175,000 | — | 0.5% | — | ||||||||||
| — | — | SOLENO THERAPEUTICS INC SOLENO THERAPEUTICS INC · COM CUSIP 834203309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.9M | 325,000 | — | 0.5% | — | ||||||||||
| — | IRONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DISC MEDICINE INC DISC MEDICINE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.9M | 170,000 | — | 0.5% | — | ||||||||||
| — | — | NURIX THERAPEUTICS INC NURIX THERAPEUTICS INC · COM CUSIP 67080M103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.9M | 700,000 | — | 0.5% | — | ||||||||||
| — | CVSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CVS HEALTH CORP CVS HEALTH CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.8M | 150,000 | — | 0.5% | — | ||||||||||
| — | COOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | COOPER COS INC COOPER COS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.7M | 150,000 | — | 0.5% | — | ||||||||||
| — | TMOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | THERMO FISHER SCIENTIFIC INC THERMO FISHER SCIENTIFIC INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.8M | 20,000 | — | 0.5% | — | ||||||||||
| — | LIVNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | LIVANOVA PLC LIVANOVA PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.5M | 150,000 | — | 0.5% | — | ||||||||||
| — | LNTHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | LANTHEUS HLDGS INC LANTHEUS HLDGS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.5M | 125,000 | — | 0.5% | — | ||||||||||
| — | TNGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TANGO THERAPEUTICS INC TANGO THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.4M | 450,000 | — | 0.5% | — | ||||||||||
| — | IONSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IONIS PHARMACEUTICALS INC IONIS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.4M | 125,000 | — | 0.4% | — | ||||||||||
| — | — | SANA BIOTECHNOLOGY INC SANA BIOTECHNOLOGY INC · COM CUSIP 799566104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.2M | 3,200,000 | — | 0.4% | — | ||||||||||
| — | CELCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CELCUITY INC CELCUITY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.1M | 80,000 | — | 0.4% | — | ||||||||||
| — | — | PROTARA THERAPEUTICS INC PROTARA THERAPEUTICS INC · COM STK CUSIP 74365U107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.1M | 1,750,000 | — | 0.4% | — | ||||||||||
| — | NVSTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ENVISTA HOLDINGS CORPORATION ENVISTA HOLDINGS CORPORATION · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.9M | 350,000 | — | 0.4% | — | ||||||||||
| — | — | BIOHAVEN LTD BIOHAVEN LTD · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.5M | 1,000,000 | — | 0.4% | — | ||||||||||
| — | — | SYNDAX PHARMACEUTICALS INC SYNDAX PHARMACEUTICALS INC · COM CUSIP 87164F105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.2M | 350,000 | — | 0.4% | — | ||||||||||
| — | VKTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VIKING THERAPEUTICS INC VIKING THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.1M | 250,000 | — | 0.4% | — | ||||||||||
| — | DFTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DEFINIUM THERAPEUTICS INC DEFINIUM THERAPEUTICS INC · COM SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.6M | 400,000 | — | 0.4% | — | ||||||||||
| — | — | BEAM THERAPEUTICS INC BEAM THERAPEUTICS INC · COM CUSIP 07373V105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.1M | 300,000 | — | 0.3% | — | ||||||||||
| — | — | REZOLUTE INC REZOLUTE INC · COM NEW CUSIP 76200L309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.1M | 2,000,000 | — | 0.3% | — | ||||||||||
| — | — | CAPRICOR THERAPEUTICS INC CAPRICOR THERAPEUTICS INC · COM NEW CUSIP 14070B309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.1M | 200,000 | — | 0.3% | — | ||||||||||
| — | IQVverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IQVIA HLDGS INC IQVIA HLDGS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.0M | 35,000 | — | 0.3% | — | ||||||||||
| — | AXSMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | AXSOME THERAPEUTICS INC. AXSOME THERAPEUTICS INC. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.9M | 35,000 | — | 0.3% | — | ||||||||||
| — | PTGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PROTAGONIST THERAPEUTICS INC PROTAGONIST THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.3M | 50,000 | — | 0.3% | — | ||||||||||
| — | — | EVOMMUNE INC EVOMMUNE INC · COM SHS CUSIP 30054Y107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.2M | 225,000 | — | 0.2% | — | ||||||||||
| — | ACHCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ACADIA HEALTHCARE COMPANY IN ACADIA HEALTHCARE COMPANY IN · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.7M | 200,000 | — | 0.2% | — | ||||||||||
| — | ZBHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ZIMMER BIOMET HOLDINGS INC ZIMMER BIOMET HOLDINGS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.5M | 50,000 | — | 0.2% | — | ||||||||||
| — | — | FORTE BIOSCIENCES INC FORTE BIOSCIENCES INC · COM NEW CUSIP 34962G208 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.9M | 150,000 | — | 0.2% | — | ||||||||||
| — | — | LB PHARMACEUTICALS INC LB PHARMACEUTICALS INC · COM SHS CUSIP 50180M108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.7M | 150,000 | — | 0.2% | — | ||||||||||
| — | — | SAVARA INC SAVARA INC · COM CUSIP 805111101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.3M | 600,000 | — | 0.2% | — | ||||||||||
| — | — | RELMADA THERAPEUTICS INC RELMADA THERAPEUTICS INC · COM CUSIP 75955J402 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.1M | 450,000 | — | 0.1% | — | ||||||||||
| — | IMCRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IMMUNOCORE HLDGS PLC IMMUNOCORE HLDGS PLC · ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.0M | 100,000 | — | 0.1% | — | ||||||||||
| — | — | MAZE THERAPEUTICS INC MAZE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.0M | 100,000 | — | 0.1% | — | ||||||||||
| — | — | TENAX THERAPEUTICS INC TENAX THERAPEUTICS INC · COM NEW CUSIP 88032L605 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.7M | 167,000 | — | 0.1% | — | ||||||||||
| — | — | INHIBIKASE THERAPEUTICS INC INHIBIKASE THERAPEUTICS INC · COM NEW CUSIP 45719W205 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.3M | 1,350,000 | — | 0.1% | — | ||||||||||
| — | OLMAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | OLEMA PHARMACEUTICALS INC OLEMA PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.2M | 150,000 | — | 0.1% | — | ||||||||||
| — | — | INVENTIVA SA INVENTIVA SA · ADS CUSIP 46124U107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.2M | 400,000 | — | 0.1% | — | ||||||||||
| — | SIONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SIONNA THERAPEUTICS INC SIONNA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.0M | 50,000 | — | 0.1% | — | ||||||||||
| — | — | UNICYCIVE THERAPEUTICS INC UNICYCIVE THERAPEUTICS INC · COM NEW CUSIP 90466Y202 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.5M | 225,000 | — | 0.1% | — |
1–86 of 86 issuers · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).